Apoptosis regulators in ovarian and endometrial tissue

Apoptosis regulators in ovarian and endometrial tissue comprise a complex network of proteins that orchestrate programmed cell death to maintain reproductive health and tissue homeostasis. This group includes the B-cell lymphoma 2 (BCL-2) family (e.g., BCL-2, Induced myeloid leukemia cell differentiation protein Mcl-1, BCL2-associated X protein), the inhibitor of apoptosis (IAP) family (e.g., X-linked inhibitor of apoptosis protein, Baculoviral IAP repeat-containing protein 5), and the caspase protease family (NIH, 2000). In the endometrium, these regulators facilitate the cyclic shedding of tissue during the menstrual cycle, while in the ovary, they govern follicular atresia and the selection of dominant follicles (Eco-vector, 2021). Dysregulation of these pathways, such as the overexpression of anti-apoptotic BCL-2 or the loss of functional Tumor protein p53, is a hallmark of gynecological malignancies like ovarian and endometrial cancers, as well as benign conditions like endometriosis (MDPI, 2021; NIH, 2005). Therapeutic strategies targeting these regulators include BCL-2 inhibitors like venetoclax and IAP antagonists like xevinapant, which aim to restore apoptotic sensitivity in resistant tumor cells (ResearchGate, 2021). However, the redundancy of these pathways and the risk of systemic toxicities, such as tumor lysis syndrome and cytopenias, present significant challenges for clinical application.

Other names

Apoptotic signaling proteinsProgrammed cell death regulatorsBCL-2 family proteinsIAP family proteinsCaspase family

Inhibition of anti-apoptotic proteins (e.g., BCL-2, MCL-1, XIAP), activation of pro-apoptotic members (e.g., BAX, BAK), and stabilization of tumor suppressors like p53 to trigger the caspase cascade and induce programmed cell death.